Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.61 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | PTGFR | P43088 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.42 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28238487 | 0.84 | FFAR1 (0.49) | FFAR1FFAR4MAOBMRGPRX4FOLH1 | |
| SCHEMBL3723396 | 0.82 | FFAR1 (0.59) | FFAR1FFAR4MAOBMRGPRX4FOLH1 | |
| SCHEMBL20551473 | 0.82 | MRGPRX4 (0.53) | FFAR1FFAR4MAOBMRGPRX4KCNH2 | |
| SCHEMBL20378818 | 0.82 | GSK3B (0.48) | FFAR1FFAR4MAOBMRGPRX4FOLH1 | |
| SCHEMBL4840290 | 0.81 | FFAR1 (0.60) | FFAR1FFAR4FOLH1PTGFRLMNA | |
| SCHEMBL2774422 | 0.79 | FFAR1 (0.48) | FFAR1FFAR4MAOBMRGPRX4KCNH2 | |
| SCHEMBL1246091 | 0.79 | FFAR1 (0.59) | FFAR1FFAR4FOLH1PTGFRLMNA | |
| SCHEMBL291194 | 0.78 | SMN1; SMN2 (0.57) | FFAR1FFAR4FOLH1 | |
| SCHEMBL3166793 | 0.78 | FFAR4 (0.53) | FFAR1FFAR4MAOB | |
| SCHEMBL3898501 | 0.78 | FFAR1 (0.54) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774031-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2020-09-15 | — | — | US | disclosed |
| US-10640451-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2020-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640451-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | GABRB3, GABRB2, GABRB1 | FFAR1 184/4885FFAR4 98/4885MAOB 83/4885 |
| US-10774031-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | GABRB3, GABRB2, GABRB1 | FFAR1 184/4885FFAR4 98/4885MAOB 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.